MBP and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: By leveraging a nanobody fused with maltose-binding protein (MBP), we have exploited a chemogenetic approach to effectively disrupt TFE3 oncofusion-mediated transcriptional condensate formation, resulting in the suppression of tRCC cell growth in vitro and in vivo.